Pivotree Inc. (CVE:PVT – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$1.10 and last traded at C$1.40, with a volume of 4450 shares. The stock had previously closed at C$1.20.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on PVT. Cormark reduced their price objective on shares of Pivotree from C$5.00 to C$3.50 in a research report on Monday, April 1st. National Bankshares lowered shares of Pivotree from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from C$3.00 to C$2.00 in a research report on Monday, May 13th. Canaccord Genuity Group boosted their price objective on Pivotree from C$1.50 to C$1.70 and gave the company a “hold” rating in a research note on Monday, May 13th. Paradigm Capital lowered their target price on shares of Pivotree from C$4.25 to C$4.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Finally, National Bank Financial downgraded Pivotree from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 10th.
View Our Latest Stock Analysis on PVT
Pivotree Stock Up 16.7 %
Pivotree Company Profile
Pivotree Inc designs, integrates, deploys, and manages digital platforms in commerce, data management, and supply chain for retail and branded manufacturers in Canada and internationally. The company offers infrastructure deployment, data transaction, subscription license, system and application triage and support, configuration management, and security services, as well as provides web and application hosting services.
Featured Articles
- Five stocks we like better than Pivotree
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- RXO Shares Surge Following New Acquisition Deal
- Business Services Stocks Investing
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- What is a Secondary Public Offering? What Investors Need to Know
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Pivotree Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pivotree and related companies with MarketBeat.com's FREE daily email newsletter.